INC Research Advances the Conversations on Co-Development Partnerships and Out-licensing Strategies at BIO 2010

Chicago, BIO International Convention 2010, May 3, 2010 – INC Research®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, is exhibiting at the BIO International Convention 2010 at booth #2838 and is featuring experts to discuss a range of hot topics in the drug development industry.

Tim Dietlin, VP, Alliance Development at INC Research, is an advocate on why CROs and sponsors should think differently about traditional clinical trial models. Clinical delivery alliance partnerships have gotten a lot of buzz lately. One aspect of these alliances that has been in the spotlight is co-development partnerships.

Tim will review the existing and evolving spectrum of co-development alliance partnerships and implications of these on the industry. He will explore the three main elements of drug development – asset and asset resources, finance and operations – and how these interrelate in a clinical delivery alliance structure. With the CRO typically in the center of this fragmented, networked model, defining its role is more important than ever to reach a highly effective and efficient drug development process. In addition, he will debate if co-development alliances are good for the industry from all perspectives.

Vice President, Regulatory Affairs and Strategic Development Wayne Whittingham is also available to speak about out-licensing drug candidates as part of a cost-control strategy, a financing strategy and/or an exit strategy. He can share the top questions sponsors should consider when designing a clinical program specifically to support product out-licensing. View his recent Foresight article on this topic here.

About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

###